PRO1102 / Genmab - LARVOL DELTA

The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity (AACR 2022) - "PRO1102 is comprised of 1) trastuzumab, a clinically and commercially validated HER2-directed antibody, 2) a cleavable, hydrophilic linker, and 3) exatecan, a topoisomerase 1 inhibitor. Tolerability was evaluated in mice and at PRO1102 dose levels associated with robust anti-tumor activity, PRO1102 was well tolerated. PRO1102 exhibits the attributes needed for an effective ADC with robust activity in a broad selection of HER2-expressing cancers."

Preclinical • Gastrointestinal Cancer • Oncology • Solid Tumor

ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer (PRNewswire) - "ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8 - 13, 2022. The presentations will highlight three late-stage preclinical programs utilizing ProfoundBio's leading ADC technology as well as advances in linker-drug development."

Preclinical • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer